Oxford-Harrington and Oxford Launch £5.25M Pediatric Oncology Program
Oxford, UK and Cleveland, Ohio, US, July 1, 2026 The Oxford-Harrington Rare Disease Centre (OHC) has announced a major...
pediatric oncology
Advertisement
US WorldMeds Secures Full FDA Approval for TECELRA
LOUISVILLE, Kentucky, June 22, 2026 US WorldMeds has announced that the U.S. Food and Drug Administration (FDA) has granted...
RedHill’s Opaganib Gains FDA Rare Pediatric Disease Status
RALEIGH, North Carolina, USA & TEL AVIV, Israel – June 9, 2026 RedHill Biopharma has received a significant regulatory...
Servier Advances OJEMDA Front-Line Brain Cancer Trial
BOSTON – May 8, 2026 Day One Biopharmaceuticals, now part of Servier Group, announced the completion of patient enrollment...
Koselugo Secures US Approval, Advancing Targeted NF1 Care
Wilmington, Delaware, November 2025 AstraZeneca has announced that Koselugo (selumetinib) has received expanded FDA approval in the United States...
Advertisement
